JWH-250

JWH-250 is a synthetic cannabinoid in the phenylacetylindole family. It contains a 2-methoxyphenylacetyl group attached to an N-pentylindole core and acts as an agonist at CB₁ and CB₂ receptors. JWH-250 was identified in herbal smoking mixtures in Europe from 2009 and was reviewed by the World Health Organization in 2014 because of concerns about harmful use and its lack of therapeutic application.

Chemistry and history

JWH-250 is 2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone. It differs from naphthoylindoles such as JWH-018 by having a methoxy-substituted phenylacetyl group rather than a naphthoyl group. It is related to JWH-203 and JWH-251, which carry different substituents on the phenylacetyl ring.

JWH-250 was first reported to the European monitoring system in October 2009 and remained in the market in subsequent years. It was found in herbal smoking blends and bulk powders (EUDA: Synthetic cannabinoids in Europe).

Pharmacology

JWH-250 binds to both CB₁ and CB₂ receptors. The WHO review describes low-nanomolar binding affinity and a slight preference for CB₁. One commonly cited study reported Ki values of approximately 11 nM at CB₁ and 33 nM at CB₂ (WHO critical review of JWH-250, 2014).

The methoxy group at the ortho position of the phenyl ring is important to the structure–activity relationship of this series. Receptor studies found that this substitution improves CB₁ affinity compared with some unsubstituted or differently substituted phenylacetylindoles (ACMD report on major cannabinoid agonists).

Reported effects

The WHO review summarised reports of cannabis-like effects and adverse reactions after use of products containing JWH-250. Reported symptoms included agitation, anxiety, confusion and cardiovascular changes. As with other synthetic cannabinoid products, the exact composition and concentration of the material were not always known.

There are no controlled human studies that define a characteristic JWH-250 experience or a reliable duration. Effects from a mixed herbal product cannot automatically be attributed to JWH-250 alone.

Clinical and forensic findings

JWH-250 was identified in commercial herbal smoking mixtures in the United States alongside JWH-018, JWH-073, JWH-200 and JWH-210. Some products contained more than one synthetic cannabinoid, which complicates the interpretation of adverse events (Logan and colleagues, 2012).

The WHO review concluded that JWH-250 had no recognised therapeutic use and that available information raised concerns about its potential to cause harm. It also noted that the evidence base for long-term effects and dependence was incomplete (WHO Expert Committee on Drug Dependence).

Toxicity and research limitations

JWH-250 has a documented history of appearance in recreational products, but the clinical literature does not establish a precise concentration-toxicity relationship. Co-exposures and changing product formulations are recurring limitations. Its long-term effects and dependence potential remain insufficiently characterised in humans.

Related compounds

JWH-250 is related to JWH-167, JWH-203 and JWH-251. These compounds share the phenylacetylindole framework but differ in the substituent attached to the phenyl ring.